SEOUL, April 24 (Yonhap) -- Lotte Biologics Co., the biotech arm of Lotte Group, said Thursday it has signed a deal with an ...

迈威生物（688062.SH），一家全产业链布局的创新型生物制药公司，宣布将于当地时间 2025 年 5 月 30 日 – 6 月 3 日在美国芝加哥举行的 2025 美国临床肿瘤学会（ASCO）年会以口头报告形式公布靶向 Nectin-4 ADC 创新药 9MW2821联合特瑞普利单抗用于局部晚期或转移性尿路上皮癌的 Ib/II 期临床研究数据。另有 3 项 ADC 临床研究数据将以壁报形式公布 ...

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the ...

Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how ...

4 As both T-DM1 and T-DXd differ in terms of their cytotoxic payloads, linker types, and drug-to-antibody ratios, scientists can directly compare how these variables affect the ADC’s efficacy and the ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr: Nandita Vijayasimha, Bengaluru Saturday, April 12, 2025, 08:00 Hrs [IST] Anti ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special ...